Welcome to BaselBC - Basel Breast Consortium
Jun 14 2016 12:30: Lunchtime meeting
Hospital, Seminar room, ZLF, 2nd floor, Hebelstrasse 20, 4031 Basel, Lunch provided
Primo Schär (DBM): Department of Biomedicine, University Basel
Hans-Jörg Senn: Tumour and Breast Center (ZeTuP), St. Gallen
Heidi Lane: Basilea Pharmaceutica International Ltd, Basel
» View poster
The Basel Breast Consortium is an interdisciplinary organization committed to the development of basic, clinical and translational research projects by supporting interdisciplinary communication and mutual education in Switzerland and neighbouring cities. The presence of outstanding basic science groups, a university hospital and a medical faculty with strong clinical oncology departments, and numerous pharma companies make Basel well-positioned to be the nexus of these collaborative activities.
To discuss, design and conduct scientific projects with the potential to advance knowledge in breast cancer basic biology and therapy to the highest level of targeted therapeutic efficacy while minimizing treatment-related toxicity.
The consortium’s mission is accomplished by regular meetings and networking opportunities among basic researchers, translational research scientists, clinicians - from academia and industry - dedicated to the study of mammary gland development, as well as breast cancer research and treatment in Switzerland and neighbouring cities. Participating clinicians and researchers may have a designated interest in basic or clinical research and originate from the fields of plastic, oncologic and oncoplastic surgery, radiation and medical oncology, gynecology, pathology, radiology and genetics. Participating basic researchers may originate, among others, from a variety of disciplines, including basic cell biology, genetics, immunology, computational biology, endocrinology and fundamental molecular biology.
We organize four joint lunchtime tandem meetings per year. The format is three 15 minutes presentations from basic/translational researchers, clinicians, and industry, while providing 15 additional minutes for discussion and networking.
We are confident that these interactions promote fruitful collaborations in the fields of breast development and breast cancer in Switzerland and neighbouring cities.